Consistently delivering outperforming cell lines leveraging extensive CLD expertise and innovative seeding platform

Camille Evenou BPI Boston 2019

CELONIC BEYOND BIOMANUFACTURING We are a Biologics Development and Manufacturing Organization specialized in Mammalian Cell Lines

From Discovery to Market Supply

Comprehensive GMP development and manufacturing for New Biological Entities and Biosimilars

Global Clientele

Innovative solutions that deliver commercial success for our customers

Total Quality Commitment Empathy, Efficiency, Excellence



YOUR TRUSTED PARTNER – FROM DISCOVERY TO MARKET SUPPLY



STRATEGIC PARTNERS





ABOUT US

LOCATIONS

1 **Basel** SWITZERLAND

> Development & GMP production Employees: 117

2 Heidelberg GERMANY

GMP production **Employees**: 173

		2	
Established	1982		
Employees	290		
CEO	Dr. Konstantin Matentzoglu		
Ownership	Private, JRS Group, Germany		

OUR EVOLUTIONARY JOURNEY





HIGH PERFORMANCE CELL LINES

INNOVATIVE INDUSTRY-LEADING CELL EXPRESSION PLATFORMS



SIMPLIFIED LICENSING MODEL (e.g. no royalties from sales)

Cell line adapted to serum-free EMA and FDA COMPLIANT MEDIA

HIGH SCALE-UP STABILITY

GMP COMPLIANT From R&D to market

Cell line in several CLINICAL TRIALS in EU/US & Asia

GEX[®]

Human cells for fully-human glycosylation

Optimized for complex and sophisticated biopharmaceutical product

Stable product quality over full run time for R&D and/or GMP



CLD CHO WORKFLOW OPTIMIZATION

Original CLD Minipool Workflow





Up to 29 weeks Up to 500 plates





C CELONIC 10

Improved Workflow Requirements

Improved timelines for CLD

- More projects / year
- Streamlined CLD process
- Same enrichment properties

Reduced amount of plates

- Same amount of clones
- Faster Handling
- More Imaging

Proof of clonality

- Higher Quality Pictures
- Computer-assisted assessment of clonality
- Automated reports

CELONIC

Definitions

Seeding Efficiency

- %Wells seeded with a single cell per plate
- Depends on seeding method



1 week after seeding



Outgrowth

- %Clonal wells growing to colonies
- Depends on seeding method and medium



Example





Introducing FACS

Capabilities

- Analyse transfected pools
- Sort highest producers
- Single cell sorting





Device

- FACSAriaTM Fusion
- Manufactured by Becton Dickinson





FACS vs Limiting Dilution – GEX Cells (Human Perfusion Cell Line)



: 15

Introducing FACS

Improvements

- No need for minipools
- Ability to screen several variations of the vector construct
- Works well with GEX cell line

Shortcomings with CHO cells

 Better seeding efficiency but lower outgrowth (much higher mortality than with Limiting Dilution)

 $\bullet \bullet \bullet \bullet$

0



Introducing VIPS & Cell Metric

Capabilities

- Gentle single cell seeding
- High resolution imaging
- Automated clonality reports







Devices

- VIPS[™] Verified In Situ Plate Seeding
- Cell Metric[®] Imager
- Manufactured by Solentim





FACS Vs VIPS Outgrowth – CHO Cells



C CELONIC 18

Media Screening with VIPS– CHO Cells



Media Optimisation with VIPS – %HSA with CHO Cells



Media Optimisation – Different recombinant HSA



C CELONIC 21

Process Improvements – CHO Cells



Introducing VIPS & Cellmetric

Capabilities

- Gentle single cell seeding
- High resolution imaging
- Automated clonality reports







Devices

- VIPS Verified In Situ Plate Seeding
- Cell Metric[®] Imager
- Manufactured by Solentim





Assurance of Clonality – Previously (CSI)



Day 0

Day 1

Day 7

Day 12 C CELONIC 24

Assurance of Clonality – Now (Solentim's Cell Metric[®])



Assurance of Clonality – Now (via Solentim's Cell Metric[®])



Day 0 Day 12 From single cell containing drop to full colony!



Summary - New FACS & VIPS Workflow



